Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, announced on Tuesday that the United States Patent and Trademark Office has issued a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralises CCL24, a novel disease target at the confluence of fibrosis and inflammation.

The new patent includes the use of CM-101 and sequence-related CCL24 antibodies to treat hepatic (liver) diseases. Presently, CM-101 is in a Phase two trial for the treatment of primary sclerosing cholangitis (PSC).

CM-101 is a monoclonal antibody that neutralises the soluble protein CCL24, a cytokine family member that can trigger self-reinforcing inflammatory and fibrotic pathways implicated in various serious progressive diseases.